{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:21:46Z","timestamp":1764829306156,"version":"3.46.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,3]]},"DOI":"10.7759\/cureus.98411","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T03:47:07Z","timestamp":1764820027000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the Therapeutic and Economic Impact of Adalimumab Versus Methotrexate in the Management of Psoriasis: A Prospective Comparative Study"],"prefix":"10.7759","author":[{"given":"Kajomi","family":"Shingala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipesh","family":"Nariya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilesh","family":"Chavda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Purvik","family":"Busa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deval","family":"Vora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke WH","year":"2015","unstructured":"Boehncke WH, Sch\u00f6n MP. Psoriasis. Lancet. 2015, 386:983-94. 10.1016\/S0140-6736(14)61909-7","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.11.013","article-title":"Psoriasis prevalence among adults in the United States","volume":"70","author":"Rachakonda TD","year":"2014","unstructured":"Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014, 70:512-16. 10.1016\/j.jaad.2013.11.013","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes MA","year":"2007","unstructured":"Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007, 445:866-73. 10.1038\/nature05663","journal-title":"Nature"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths CE","year":"2007","unstructured":"Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007, 370:263-71. 10.1016\/S0140-6736(07)61128-3","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.03.028","article-title":"Attributable risk estimate of severe psoriasis on major cardiovascular events","volume":"124","author":"Mehta NN","year":"2011","unstructured":"Mehta NN, Yu Y, Pinnelas R, Krishnamoorthy P, Shin DB, Troxel AB, Gelfand JM. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011, 124:775. 10.1016\/j.amjmed.2011.03.028","journal-title":"Am J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.72462","article-title":"Prevalence of metabolic syndrome in patients with psoriasis","volume":"76","author":"Nisa N","year":"2010","unstructured":"Nisa N, Qazi MA. Prevalence of metabolic syndrome in patients with psoriasis. Indian J Dermatol Venereol Leprol. 2010, 76:662-5. 10.4103\/0378-6323.72462","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis","volume":"156","author":"Armstrong AW","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A, et al.. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020, 156:258-69. 10.1001\/jamadermatol.2019.4029","journal-title":"JAMA Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14816","article-title":"British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016","volume":"175","author":"Warren RB","year":"2016","unstructured":"Warren RB, Weatherhead SC, Smith CH, Exton LS, Mohd Mustapa MF, Kirby B, Yesudian PD. British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. Br J Dermatol. 2016, 175:23-44. 10.1111\/bjd.14816","journal-title":"Br J Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03389.x","article-title":"European S3-guidelines on the systemic treatment of psoriasis vulgaris","volume":"23","author":"Pathirana D","year":"2009","unstructured":"Pathirana D, Ormerod AD, Saiag P, et al.. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009, 23:1-70. 10.1111\/j.1468-3083.2009.03389.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08284.x","article-title":"Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial","volume":"158","author":"Flytstr\u00f6m I","year":"2008","unstructured":"Flytstr\u00f6m I, Stenberg B, Svensson A, Bergbrant IM. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol. 2008, 158:116-21. 10.1111\/j.1365-2133.2007.08284.x","journal-title":"Br J Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2014.873701","article-title":"Treating moderate to severe psoriasis - best use of biologics","volume":"10","author":"Lynch M","year":"2014","unstructured":"Lynch M, Kirby B, Warren RB. Treating moderate to severe psoriasis - best use of biologics. Expert Rev Clin Immunol. 2014, 10:269-79. 10.1586\/1744666X.2014.873701","journal-title":"Expert Rev Clin Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter A","year":"2008","unstructured":"Menter A, Tyring SK, Gordon K, et al.. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008, 58:106-15. 10.1016\/j.jaad.2007.09.010","journal-title":"J Am Acad Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat JH","year":"2008","unstructured":"Saurat JH, Stingl G, Dubertret L, et al.. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008, 158:558-66. 10.1111\/j.1365-2133.2007.08315.x","journal-title":"Br J Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter A","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al.. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019, 80:1029-72. 10.1016\/j.jaad.2018.11.057","journal-title":"J Am Acad Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita J","year":"2017","unstructured":"Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017, 76:377-90. 10.1016\/j.jaad.2016.07.064","journal-title":"J Am Acad Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000250839","article-title":"Severe psoriasis - oral therapy with a new retinoid","volume":"157","author":"Fredriksson T","year":"1978","unstructured":"Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica. 1978, 157:238-44. 10.1159\/000250839","journal-title":"Dermatologica"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use","volume":"19","author":"Finlay AY","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994, 19:210-16. 10.1111\/j.1365-2230.1994.tb01167.x","journal-title":"Clin Exp Dermatol"},{"key":"ref18","unstructured":"MrMed. Adalipca 40 mg injection. Accessed. February 28, 2025: https:\/\/www.mrmed.in\/medicines\/adalipca-40mg-injection."},{"key":"ref19","unstructured":"Healthkind Pharma. Adalirel 40 mg adalimumab 40 mg injection. Accessed. February 28, 2025: https:\/\/www.healthkindpharma.com\/adalimumab.html."},{"key":"ref20","unstructured":"IndiaMART. Adalimumab 40 mg injection. Accessed. February 28, 2025: https:\/\/www.indiamart.com\/proddetail\/adalimumab-40mg-injection-24206701312.html."},{"key":"ref21","unstructured":"PharmEasy. Mtx 7.5 mg strip of 10 tablets. Accessed. February 28, 2025: https:\/\/pharmeasy.in\/online-medicine-order\/mtx-7-5mg-tablet-10-s-226049."},{"key":"ref22","unstructured":"Netmeds. Folitrax 7.5 mg tablet 10's. Accessed. February 28, 2025: https:\/\/www.netmeds.com\/prescriptions\/folitrax-7-5mg-tablet-10-s."},{"key":"ref23","unstructured":"Chemist Online. Methotrexate tablets IP 7.5 mg. Accessed. February 28, 2025: https:\/\/chemistonline.in\/shop\/janaushadhi\/methotrexate-tablets-ip-7-5-mg\/."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.72443","article-title":"Psoriasis in India: prevalence and pattern","volume":"76","author":"Dogra S","year":"2010","unstructured":"Dogra S, Yadav S. Psoriasis in India: prevalence and pattern. Indian J Dermatol Venereol Leprol. 2010, 76:595-601. 10.4103\/0378-6323.72443","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.5264","article-title":"Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011","volume":"149","author":"Armstrong AW","year":"2013","unstructured":"Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013, 149:1180-5. 10.1001\/jamadermatol.2013.5264","journal-title":"JAMA Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2218504","article-title":"Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience","volume":"34","author":"Maurelli M","year":"2023","unstructured":"Maurelli M, Girolomoni G, Gisondi P. Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience. J Dermatolog Treat. 2023, 34:2218504. 10.1080\/09546634.2023.2218504","journal-title":"J Dermatolog Treat"},{"key":"ref27","article-title":"Efficacy of adalimumab compared with methotrexate or placebo stratified by baseline BMI in a randomized placebo-controlled trial in patients with psoriasis","volume":"14","author":"Prussick R","year":"2015","unstructured":"Prussick R, Unnebrink K, Valdecantos WC. Efficacy of adalimumab compared with methotrexate or placebo stratified by baseline BMI in a randomized placebo-controlled trial in patients with psoriasis. J Drugs Dermatol. 2015, 14:864-8.","journal-title":"J Drugs Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153740","article-title":"Safety and efficacy of methotrexate in psoriasis: a meta-analysis of published trials","volume":"11","author":"West J","year":"2016","unstructured":"West J, Ogston S, Foerster J. Safety and efficacy of methotrexate in psoriasis: a meta-analysis of published trials. PLoS One. 2016, 11:10.1371\/journal.pone.0153740","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders GD","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, et al.. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016, 316:1093-103. 10.1001\/jama.2016.12195","journal-title":"JAMA"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.7365\/JHPOR.2021.1.2","article-title":"Cost per responder analysis of biologics in moderate-to-severe plaque psoriasis in Indian healthcare setting","volume":"1","author":"Gokhale S","year":"2021","unstructured":"Gokhale S, Chatterjee M, Arora S, Kawatra P. Cost per responder analysis of biologics in moderate-to-severe plaque psoriasis in Indian healthcare setting. J Health Policy Outcomes Res. 2021, 1:9-15. 10.7365\/JHPOR.2021.1.2","journal-title":"J Health Policy Outcomes Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/427205-evaluation-of-the-therapeutic-and-economic-impact-of-adalimumab-versus-methotrexate-in-the-management-of-psoriasis-a-prospective-comparative-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T03:47:13Z","timestamp":1764820033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/427205-evaluation-of-the-therapeutic-and-economic-impact-of-adalimumab-versus-methotrexate-in-the-management-of-psoriasis-a-prospective-comparative-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.98411","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,3]]}}}